Low-Molecular-Weight Heparins for the Prevention and Treatment of Venous Thromboembolism

Dl, Ornstein; Yg, Hong-Dice; Papini,

doi:10.1093/milmed/166.7.593

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In hip fracture patients, LMWH or heparinoids reduce the risk of DVT by 44% 2 . As a result of their efficacy, safety, predictability and ease of use, LMWHs are widely regarded as the anticoagulants of choice for the prevention of VTE 8–12 …”

Section: Prevention Of Venous Thromboembolism After Orthopaedic Surgerymentioning

confidence: 99%

The Design of Venous Thromboembolism Prophylaxis Trials: Is Enoxaparin More Effective Than Fondaparinux?

Lalourcey¹

2003

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYThe aim of thromboprophylaxis is to minimise the incidence of clinically relevant venous thromboembolism (VTE) but in many trials designed to determine the efficacy of thromboprophylactic agents, asymptomatic VTE is included in the primary endpoint. Since asymptomatic events occur much more frequently than symptomatic events, they dominate the results. Data from trials comparing the thromboprophylactic efficacy of enoxaparin and fondaparinux in orthopaedic surgical patients are used to demonstrate that asymptomatic and symptomatic endpoints may yield different conclusions. There was no difference between these agents in the incidence of symptomatic VTE. Efficacy and safety results of thromboprophylactic studies are affected by other aspects of trial design such as the dose of each agent and the timing of treatment initiation and endpoint assessment. Such factors should be considered when designing clinical trials and evaluating their results.

show abstract

Section: Prevention Of Venous Thromboembolism After Orthopaedic Surgerymentioning

confidence: 99%

The Design of Venous Thromboembolism Prophylaxis Trials: Is Enoxaparin More Effective Than Fondaparinux?

Lalourcey¹

2003

Int J Clinical Practice

View full text Add to dashboard Cite

show abstract

Tinzaparin

Wong¹

2002

Heart Disease

View full text Add to dashboard Cite

Low-molecular-weight heparins (LMWH) are efficacious agents that offer clinical and pharmacoeconomic advantages over unfractionated heparin (UFH) for the treatment of ACS and venous thromboembolism. Tinzaparin is a LMWH approved for the treatment of deep venous thrombosis with and without pulmonary embolism, when used in conjunction with warfarin. In studies with hospitalized patients who had deep venous thrombosis or pulmonary embolism, tinzaparin was at least as efficacious as UFH, with fewer adverse bleeding events. It is also efficacious for thromboembolic prophylaxis in patients undergoing general and orthopedic surgery. Studies have shown that tinzaparin is at least as effective as UFH for patients undergoing surgery and in other patients at risk for developing thromboembolism. It is currently not recommended for use in patients with ischemic strokes. There are minimal data available regarding its use in the management of patients with unstable angina (UA) and non-ST-segment elevation myocardial infarction.

show abstract

Low-Molecular-Weight Heparins for the Prevention and Treatment of Venous Thromboembolism

Cited by 2 publications

References 0 publications

The Design of Venous Thromboembolism Prophylaxis Trials: Is Enoxaparin More Effective Than Fondaparinux?

The Design of Venous Thromboembolism Prophylaxis Trials: Is Enoxaparin More Effective Than Fondaparinux?

Tinzaparin

Contact Info

Product

Resources

About